Citation

Battley JE, Oconnor M, Barron TI, O'reilly S. Ir. Med. J. 2015; 108(6): e1.

Copyright

(Copyright © 2015, Winstone Publishing)

DOI

unavailable

PMID

unavailable

Abstract

Sir Tamoxifen has a well-established role in the management of oestrogen-receptor positive breast cancer halving the 5-year recurrence risk of early stage breast cancer, reducing mortality and controlling metastasis. It is an inactive pro-drug which is activated by the hepatic cytochrome P450 system. © 2015, Irish Medical Association. All rights reserved.

Language: en

Keywords

human; depression; suicide attempt; antidepressant agent; citalopram; fluoxetine; mirtazapine; noradrenalin uptake inhibitor; paroxetine; sertraline; venlafaxine; tamoxifen; breast cancer; cancer risk; cytochrome P450; drug interaction; cancer recurrence; cytochrome P450 2D6; estrogen receptor; Letter; afimoxifene; cytochrome P450 2D6 inhibitor; endoxifen